



## NEWS RELEASE


Encure Biotherapeutics, Inc.  
Texas Medical Center · Houston, Texas  
[www.encurebio.com](http://www.encurebio.com)

FOR IMMEDIATE RELEASE

# Encure Biotherapeutics CEO Dr. JC Bose Rajendran Joins “AI in BioTech” Panel at TMC Innovation Factory

*Panel at the BiteLabs Digital Health, AI & Innovation Summit examined where artificial intelligence is changing drug discovery and molecular science, and where the hard problems remain*

**HOUSTON, Texas — October 12, 2026** — Encure Biotherapeutics, Inc., an AI-native therapeutics company based at the Texas Medical Center, today announced that its Founder, Chief Executive Officer and Chief Scientific Officer, **Dr. JC Bose Rajendran, M.Pharm, PhD**, served as a panelist on the “AI in BioTech” panel at the BiteLabs Digital Health, AI & Innovation Summit, held on Thursday, August 27, 2026, at TMC Innovation Factory in Houston.



*Dr. JC Bose Rajendran, CEO of Encure Biotherapeutics, speaking on the AI in BioTech panel at TMC Innovation Factory, Houston.*

The panel, subtitled “Where AI meets drug discovery and molecular science,” brought together perspectives from therapeutics development, health-data privacy and venture investment. Dr. Rajendran was joined by Alison Brunelle, Privacy Program Lead at Verily Health (formerly Alphabet), and

Hendra Hoang, Venture Partner at Novellus Ventures. The session was hosted by Dr. Azeem Alam, Co-Founder of BiteWorld and Venture Partner at EWOR.

Drawing on Encure's work building its SWATI-AI generative design engine and a portfolio of programs across cardiovascular disease, oncology, neuroscience and drug safety, Dr. Rajendran focused on a practical question: how much of what AI generates can a drug-development program actually use?

## Key discussion themes

- **From generative output to actionable candidates.** The gap between what generative models propose and what a program can realistically synthesize, test and advance in target and molecule design.
- **ADMET prediction and data quality.** Why absorption, distribution, metabolism, excretion and toxicity predictions are only as reliable as the labels they are trained on, and how teams should weigh those limits.
- **Organoid-based safety screening.** The role of human organoid models in catching safety liabilities earlier and narrowing the gap between animal studies and human outcomes.
- **Delivery-system design.** Where the design of drug-delivery systems, such as lipid nanoparticles and nanocarriers, is tractable computationally today, and where experiment still has to lead.

*"AI can now generate more candidate molecules in an afternoon than a lab can make in a year. The real question is which of those designs a program can act on, and that comes down to the quality of the data behind the predictions and an honest view of what still has to be proven at the bench. Conversations like this one, with privacy, investment and drug-development perspectives in the same room, are how the field gets that balance right."*

— Dr. JC Bose Rajendran, M.Pharm, PhD, Founder, CEO & CSO, Encure Biotherapeutics

The summit, organized by BiteWorld and BiteLabs, brought together clinicians, founders, investors and industry leaders for a day of sessions on data privacy, building responsibly with AI in healthcare, clinician-entrepreneur pitches and a HealthTech Shark Tank.



The AI in BioTech panel on stage at TMC Innovation Factory.



Attendees at the BiteLabs Digital Health, AI & Innovation Summit.

## **About Encure Biotherapeutics**

Encure Biotherapeutics, Inc. is an AI-native therapeutics company headquartered at the Texas Medical Center in Houston, Texas. The company operates on a hub-and-spoke model: its SWATI-AI generative design engine serves as the central hub, supporting therapeutic programs in cardiovascular disease, oncology, neuroscience and drug safety. Encure pairs computational design with experimental validation through academic and clinical collaborations, and funds early development with a non-dilutive-first strategy. Learn more at [www.encurebio.com](http://www.encurebio.com).

## **About BiteLabs and BiteWorld**

BiteWorld, co-founded by Dr. Zac Hana, works to shape the future of healthcare, healthtech and pharma through education and policy. Its BiteLabs program convenes clinicians, innovators and investors through events including the BiteLabs Digital Health, AI & Innovation Summit.

## **Media Contact**

**Encure Biotherapeutics, Inc.**

Email: [Rajendiren@encurebio.com](mailto:Rajendiren@encurebio.com)

Web: [www.encurebio.com](http://www.encurebio.com)

**###**